The impact of value-based benefit design on adherence to diabetes medications: A propensity score-weighted difference in difference evaluation

Value in Health

Volumn 13, Issue 6, 2010, Pages 846-852

  Zeng, Feng ^a   An, Jae Jin ^b   Scully, Robert ^c   Barrington, Christina ^c   Patel, Bimal V ^a   Nichol, Michael B ^b  

^a MedImpact Healthcare Systems Inc   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Health Alliance Medical Plans   (United States)

Author keywords

adherence; compliance; diabetes; difference in difference method; propensity score; value based benefit design

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INCRETIN; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG COST; EVALUATION; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; SCORING SYSTEM; VALUE BASED BENEFIT DESIGN;

EID: 77956360952     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00730.x     Document Type: Article

References (34)

1. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff 2007 26 : w195 203.
2. Fendrick AM, Smith DG, Chernew ME. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 2001 7 : 861 867.
3. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005 43 : 521 530.
4. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004 204 : 2344 2350.
5. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of evidence. Am J Manag Care 2005 11 : 730 740.
6. Rosen AB. Grounding coverage in value: a paradigm for linking quality and costs. Med Care 2006 44 : 389 391.
7. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 2005 11 (suppl. SP170 6.
8. Goldman DP, Joyce GF, Haraca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care 2006 12 : 21 8.
9. Nicholson S. The effect of cost sharing on employees with diabetes. Am J Manag Care 2006 12 : SP20 6.
10. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff 2008 27 : 103 112.
11. Demand grows for value-based Rx plans: as insurers expand offering, ROI is elusive. Scottsdale, AZ : Atlantic Information Services, Inc., Drug Benefit News 2008.
12. Fairman KA, Curiss FR. Making the world safe for evidence-based policy: let's slay the biases in research on value-based insurance design. J Manag Care Pharm 2008 14 : 198 204.
13. US Congress. S1040, Seniors Medication Copayment Reduction Act of 2009. 111th Congress, 1st Session, introduced May 14 2009.
14. US Congress. HR 3590, Patient Protection and Affordable Care Act, 111th Congress, 1st Session. Section 2713 (c).
15. Pladevall M, Divine G, Williams LK, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004 27 : 2800 2805.
16. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1C in type 2 diabetes. Ann Pharmacother 2004 38 : 1357 1362.
17. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002 25 : 1015 1021.
18. Grant R, Adams AL, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007 30 : 807 812.
19. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004 10 : 144 151.
20. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006 166 : 1836 1841.
21. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004 27 : 2149 2153.
22. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004 27 : 1218 1224.
23. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007 33 : 1014 1029.
24. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983 70 : 41 55.
25. Fu AZ, Dow WH, Liu GG. Propensity score and difference-in-difference methods: a study of second-generation antidepressant use in patients with bipolar disorder. Health Serv Outcomes Res Methodol 2007 7 : 23 38.
26. King G, Zeng L. Logistic regression in rate events data. Pol Anal 2001 9 : 137 163.
27. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006 9 : 377 385.
28. Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003 41 : 84 99.
29. Rubin DB. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol 2001 2 : 169 188.
30. Hirano K, Imbens GW. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001 2 : 259 278.
31. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004 23 : 2937 2960.
32. Boyle JP, Honeycutt AA, Narayan KMV, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001 24 : 1936 1940.
33. Berger J. Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy. Am J Manag Care 2007 13 : S55 8.
34. Philips LS, Branch WT Jr., Cook CB, et al. Clinical inertia. Ann Intern Med 2001 9 : 825 834.